Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
HUTCHMED (China) Limited - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
HCM
Nasdaq
2834
www.hutch-med.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for HUTCHMED (China) Limited
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
- Jan 14th, 2025 4:00 am
Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week
- Jan 5th, 2025 9:56 am
Hutchmed divests 45% interest in Shanghai Hutchison for $608M
- Jan 2nd, 2025 2:15 pm
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy
- Jan 2nd, 2025 12:00 am
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
- Jan 1st, 2025 10:46 am
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
- Dec 13th, 2024 12:00 am
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy
- Dec 12th, 2024 4:00 am
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
- Dec 4th, 2024 12:00 am
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer
- Dec 3rd, 2024 10:00 am
HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms
- Nov 28th, 2024 10:30 am
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
- Nov 22nd, 2024 4:30 am
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
- Nov 20th, 2024 9:30 am
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
- Nov 6th, 2024 4:00 am
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
- Oct 31st, 2024 8:30 am
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
- Oct 16th, 2024 4:30 am
HUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ...
- Oct 9th, 2024 7:30 pm
HUTCHMED (China) (LON:HCM) shareholders are up 17% this past week, but still in the red over the last three years
- Oct 1st, 2024 10:14 am
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
- Sep 26th, 2024 12:51 pm
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
- Sep 24th, 2024 7:00 am
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
- Sep 19th, 2024 6:30 am
Scroll